Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 1.00 |
| ▸ | CA1 | P00915 | 13/20 | 0.64 |
| ▸ | CA9 | Q16790 | 11/20 | 0.64 |
| ▸ | CA4 | P22748 | 10/20 | 0.64 |
| ▸ | CA12 | O43570 | 6/20 | 0.62 |
| ▸ | CA3 | P07451 | 6/20 | 0.62 |
| ▸ | CA6 | P23280 | 6/20 | 0.62 |
| ▸ | CA5A | P35218 | 6/20 | 0.62 |
| ▸ | CA7 | P43166 | 6/20 | 0.62 |
| ▸ | CA13 | Q8N1Q1 | 6/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.62 |
| ▸ | CA5B | Q9Y2D0 | 6/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22138550 | 0.99 | CA2 (0.97) | CA2CA1CA9CA4CA12 | |
| SCHEMBL22118521 | 0.87 | CA2 (1.00) | CA2CA1CA9CA4CA12 | |
| SCHEMBL28412937 | 0.86 | CA2 (0.76) | CA2CA1CA9CA4NPC1 | |
| SCHEMBL28417100 | 0.86 | CA2 (0.76) | CA2CA1CA9CA4CA12 | |
| SCHEMBL22118511 | 0.86 | CA2 (0.97) | CA2CA1CA9CA4CA12 | |
| SCHEMBL28412714 | 0.83 | CA2 (0.71) | CA2CA1CA9CA4CA12 | |
| SCHEMBL28417793 | 0.82 | CA2 (0.69) | CA2CA1CA9CA4CA12 | |
| SCHEMBL28409743 | 0.82 | CA2 (0.69) | CA2CA1CA9CA4CA12 | |
| SCHEMBL28412650 | 0.81 | CA2 (0.68) | CA2CA1CA9CA4CA12 | |
| SCHEMBL24599314 | 0.80 | CA2 (0.87) | CA2CA1CA9CA4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213047-A1 | CARBONIC ANHYDRASE INHIBITORS FOR TREATMENT OF NEISSERIA GONORRHOEAE INFECTION | PURDUE RESEARCH FOUNDATION (US) | 2022-07-07 | — | — | US | disclosed |
| WO-2020131980-A1 | CARBONIC ANHYDRASE INHIBITORS AND ANTIBIOTICS AGAINST MULTIDRUG RESISTANT BACTERIA | PURDUE RESEARCH FOUNDATION (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213047-A1 | CARBONIC ANHYDRASE INHIBITORS FOR TREATMENT OF NEISSERIA GONORRHOEAE INFECTION | CA4, CA7, CA9 | CA2 6/4885CA1 11/4885CA9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.